Swine leucocyte antigen (SLA) class II molecules on porcine (p) cells play a crucial role in xenotransplantation as activators of recipient human CD4 + T cells. A human dominant-negative mutant class II transactivator (CIITA-DN) transgene under a CAG promoter with an endotheliumspecific Tie2 enhancer was constructed. CIITA-DN transgenic pigs were produced by nuclear transfer/embryo transfer. CIITA-DN pig cells were evaluated for expression of SLA class II with/without activation, and the human CD4 + T-cell response to cells from CIITA-DN and wild-type (WT) pigs was compared. Lymphocyte subset numbers and T-cell function in CIITA-DN pigs were compared with those in WT pigs. The expression of SLA class II on antigen-presenting cells from CIITA-DN pigs was significantly reduced (40-50% reduction compared with WT; P < 0Á01), and was completely suppressed on aortic endothelial cells (AECs) even after activation (100% suppression; P < 0Á01). The human CD4 + T-cell response to CIITA-DN pAECs was significantly weaker than to WT pAECs (60-80% suppression; P < 0Á01). Although there was a significantly lower frequency of CD4 + cells in the PBMCs from CIITA-DN (20%) than from WT (30%) pigs (P < 0Á01), T-cell proliferation was similar, suggesting no significant immunological compromise. Organs and cells from CIITA-DN pigs should be partially protected from the human cellular immune response.
Introduction
The primate T-cell response to pig antigens involves both direct and indirect pathways. [1] [2] [3] [4] Porcine (p) stimulator cells are able to directly activate human (h) T cells, reflecting productive interaction between human T-cell receptors and swine leucocyte antigen (SLA) class I and class II peptide complexes across the species barrier. 5 In xenotransplantation (xenoTx), two donor cell types are likely to be the major stimulators of direct T-cell recognition: (i) the migratory passenger leucocytes known as antigen-presenting cells (APCs), including dendritic cells, and (ii) SLA class II-positive vascular endothelial cells (ECs). Although pAPCs are transient components in the graft, pig vascular ECs are usually permanently present in the xenograft. Unlike human aortic ECs (AECs), pAECs constitutively express co-stimulatory molecules (e.g. CD80/86). 6, 7 This is probably an important factor contributing to rejection of pig xenografts and so relatively intense immunosuppressive therapy is required in Abbreviations: AEC, aortic endothelial cell; CIITA-DN, MHC Class II transactivator dominant-negative mutant; EC, endothelial cell; GTKO, a1,3-galactosyltransferase gene-knockout; h, human; p, porcine; PBMC, peripheral blood mononuclear cell; SLA, swine leucocyte antigen; Tx, transplantation; WT, wild-type 
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pig-to-primate xenoTx. However, intensive immunosuppression, especially long-term, results in impaired immunity, which is associated with susceptibility to infection. 8 In xenoTx, there is the possibility that specific anti-graft immune responses can be reduced by genetic modification of the pig. 9 MHC class II molecules on donor cells play a crucial role in allo/xenoTx as activators of recipient CD4 + T cells. The class II transactivator (CIITA) has been termed a master regulator for MHC class II. 10 Some mutations of CIITA have been found to account for deficiency of MHC class II expression in patients with severe immunodeficiency, i.e. bare lymphocyte syndrome. 11 Variants of the CIITA gene, especially its dominant-negative mutant (DN), have been designed and constructed to interfere with expression of the class II gene. High sequence homology (87Á4%) between human and pig CIITA 12 allowed us to use an hCIITA mutant to reduce MHC class II (SLA class II) expression in pigs. Human CIITA-DN transgenic pigs on a wild-type (WT) background were produced as potential sources of organs/tissues/cells for xenoTx.
The aims of this study were to investigate in vitro (i) the expression of SLA class II on pAECs (with/without activation) and on peripheral blood mononuclear cells (PBMCs) (as APCs) from CIITA-DN pigs, (ii) the hCD4 + T-cell response to cells from CIITA-DN pigs, and (iii) the immune status of CIITA-DN pigs. Our results suggest that the Tx of organs from CIITA-DN pigs into primates will be associated with reduced hCD4 + T-cell-mediated rejection.
Materials and methods

Animals
The transfection of CIITA-DN vector to porcine fetal fibroblasts and the production of the CIITA-DN pigs by nuclear transfer were carried out by Revivicor Inc. (Blacksburg, VA), as previously described. 13 They were Large White/Landrace/Duroc cross-bred pigs, and were all of WT background. All CIITA-DN pigs were as healthy and free of infections as WT pigs housed under the same conditions at Revivicor. Body weight increased appropriately and by 18 months of age had reached > 250 kg, breeding capacity was normal, and there were no adverse observations at necropsy (not shown). Two CIITA-DN pigs (12 and 18 months old) and three WT siblings (not CIITA-DN transgenic) were killed to collect tissues and to culture pAECs. CIITA-DN pigs were confirmed by detecting the hCIITA-DN gene using PCR (see Supplementary material, Data S1).
All 
Cell culture
Porcine AECs were cultured as previously described.
14 Activation of sub-confluent pAECs was carried out by coculture with recombinant porcine interferon-c (pIFN-c; 40 ng/ml; Serotec, Raleigh, NC) with/without porcine tumour necrosis factor-a (TNF-a; 50 ng/ml; Serotec) for adequate periods.
Human CD4 + T-cell proliferation assays
The PBMCs and hCD4 + T cells were isolated as previously described. 15 Mixed lymphocyte reactions were carried out as previously described. 4, 15 Briefly, isolated hCD4 + T cells (as responders) (2 9 10 5 cells/well) were co-cultured with irradiated (2500 cGy) pAECs (2 9 10 4 cells/well) with/ without activation by pIFN-c, or isolated hCD4 + T cells (as responders) (1 9 10 5 cells/well) were co-cultured with irradiated (2500 cGy) pPBMCs (4 9 10 5 cells/well). The cells were cultured at 37°in 5% CO 2 for 7 days (pAEC stimulators) or 5 days (pPBMC stimulators).
Statistical methods
All results are expressed as mean AE SEM. The statistical significance of differences was determined by Student's t-test or non-parametric tests, as appropriate, using GRAPH-PAD PRISM version 4 (Graphpad Software, San Diego, CA). A P-value < 0Á05 was considered to be statistically significant.
Results
Expression of hCIITA-DN mRNA in CIITA-DN pig organs An hCIITA-DN transgene under a CAG promoter with an endothelium-specific enhancer (Tie 2) was constructed ( Fig. 1) and CIITA-DN pigs were generated by nuclear transfer of the hCIITA-DN transfected porcine fetal fibroblasts. Significant levels of hCIITA-DN mRNA were confirmed in tissues obtained from heart, lung, liver, kidney and aorta in CIITA-DN pigs (see Supplementary material, Fig. S1 ).
Human CIITA-DN suppresses the expression of pCIITA mRNA and SLA class II on pig tissues (e.g. aorta) and cultured pAECs
The expression of SLA class II on the vascular endothelium (aorta, spleen, pancreas, lymph nodes) and leucocytes (in the spleen and lymph nodes) from CIITA-DN pigs was reduced compared with that from WT pigs (Fig. 2) .
Cultured CIITA-DN pAECs were activated with pIFN-c for 72 hr. Expression of pCIITA mRNA was investigated by reverse transcription PCR and quantitative real-time PCR, and the results were compared with WT pAECs. Reverse transcription PCR demonstrated that pCIITA mRNA was significantly suppressed on CIITA-DN pAECs even after activation with pIFN-c (Fig. 3a) . Minimal increases in pCI-ITA mRNA were detected during activation, but the levels were still lower than in WT pAECs (Fig. 3b) .
Although the levels of pCIITA mRNA were increased in CIITA-DN pAECs after activation (Fig. 3) , the expression of SLA class II (DR and DQ) on pAECs was strongly suppressed (Fig. 4a,b ) even after activation with pIFN-c AE pTNF-a, indicating that hCIITA-DN strongly inhibits the function of pCIITA. In contrast to SLA class II, the expression of SLA class I on pAECs was up-regulated similarly on WT and CIITA-DN pAECs after activation with pIFN-c (data not shown).
Reduction of anti-pig hCD4
+ T-cell responses by constitutive suppression of SLA class II expression
The hCD4 + T-cell response to CIITA-DN pAECs was significantly lower than to WT (sibling) pAECs in both non-activated and activated states ( Fig. 5a ) (P < 0Á01). The reductions in the response of hCD4 + T cells to nonactivated and activated CIITA-DN pAECs compared with those of WT pAECs were 60% and 70%, respectively. It is important to note that the suppressive effect of CIITA-DN was consistently found throughout the 9-day period of mixed lymphocyte culture (Fig. 5b) .
SLA class II expression on PBMCs from CIITA-DN pigs was down-regulated and resulted in suppression of the hCD4 + T-cell response
In the generation of CIITA-DN pigs, an endothelialspecific enhancer was used to enhance the tissue-specific expression hCIITA-DN in pAECs. As well as suppression of SLA class II in pAECs, CIITA-DN pigs also showed significantly down-regulated SLA class II expression on APCs (B cells) ( intensity of SLA class II expression on B cells from CIIT-A-DN pigs was 90% compared with WT pigs (Fig. 6b ).
There was a significantly lower response of hCD4 + T cells to CIITA-DN pPBMCs compared with WT pig and human PBMCs (P < 0Á01) (Fig. 6c) . The percentage reductions of the hCD4 + T-cell responses to CIITA-DN stimulators were 50% and 30%, respectively, compared with WT pig and human PBMC stimulators.
Immune status of CIITA-DN pigs is similar to that of WT pigs
Lymphocyte subset numbers and T-cell function were compared between CIITA-DN and WT pigs. Although there was no significant difference in the frequencies of 
Discussion
As both pigs and humans normally express MHC class II on their ECs upon activation, 16, 17 donor MHC class II molecules might play a crucial role in graft rejection by activation of the recipient's direct T-cell response. The accessory interactions for direct T-cell recognition of pAPCs by human T cells are largely intact. 18 It has been shown that direct xenorecognition of SLA class II by human T cells is greater than direct allorecognition of HLA class II by human T cells. 4 AECs are permanent components of grafts. However, unlike hAECs, pAECs constitutively express co-stimulatory molecules. 6, 7, 19 This species difference would be likely to result in greater immunogenicity of pig xenografts compared with human allografts. In addition, donor-derived passenger leucocytes, including APCs, migrate into host lymphoid tissues after xenograft placement and may be responsible for initiating graft rejection through the direct pathway (as in allograft rejection). [20] [21] [22] Therefore, the direct route of xenoantigen presentation (activation of human T cells by both pAPCs and ECs) will be functional after pig-toprimate xenoTx.
There are several potential strategies for reducing the human T-cell immune response to pig xenografts. [23] [24] [25] [26] Suppression of these interactions by administering costimulatory blockade agents has been widely used in experimental models. 23, [27] [28] [29] In contrast to non-specific immune suppression, it would be ideal if only the donorspecific responses could be suppressed, possibly, for example, by the xenoTx of organs from pCTLA4-Ig transgenic pigs. 13, 19 One potential strategy would be to suppress MHC class II expression on ECs in transplanted organs, 12 with a view to diminishing their long-term immunogenicity. We constructed a mutated hCIITA gene lacking the coding regions for the N-terminal domain, with the objective of creating DN mutants. The aim was that the mutated hCI-ITA proteins, lacking transcription activation activity, would bind to the promoter regions of SLA class II genes and competitively inhibit the binding of endogenous pCI-ITA. However, high levels of constitutive expression of hCIITA-DN, particularly in the thymus and APCs (e.g. by using a CIITA-DN construct under the control of a widely expressed constitutive promoter or by gene knockout), is associated with a decreased number of pCD4 + T cells in the blood, with concomitant risks of infection. 30 Such pigs would be immunodeficient, as are patients with the bare lymphocyte syndrome. 11 Therefore, an hCIITA-DN transgene under a CAG promoter with an endothelium-specific enhancer was constructed to ensure high-level expression of hCIITA-DN on endothelium but modest expression on lymphocytes. Indeed, the expression of SLA class II on pACEs was significantly suppressed even after activation by cytokines.
Because of the limited number of pigs available to us, the number of CIITA-DN pigs used for the investigation of SLA class II expression on pAECs was small (n = 2). It will be important to confirm the effect of CIITA-DN on the down-regulation of SLA class II on pAECs when this genetic modification is combined with others, e.g. in a1,3-galactosyltransferase gene-knockout (GTKO) pigs transgenic for one or more human complement-regulatory proteins.
In contrast to surface expression of SLA class II, there was still a significant level of pCIITA mRNA in CIITA-DN pAECs although the level was less than that in WT pAECs. The reduced mRNA expression of pCIITA in both non-activated and activated CIITA-DN pAECs is explained by the effect of hCIITA-DN. However, the mechanism of remaining expression and up-regulated expression of pCIITA after activation is unclear.
Interferon-c inhibits the functional activity of CMV promoter/enhancers, 31 which were used for hCIITA-DN, and therefore it is possible that IFN-c might interfere in the functional activity of hCIITA-DN. The extent of suppression of SLA class II expression would be associated with the level of competitive inhibitors of hCIITA-DN. Whether other mechanisms of down-regulation of SLA class II in CIITA-DN pigs, e.g. auto-regulation, or competitive inhibition by hCIITA-DN binding to transactivator receptors, result in down-regulation of transactivator expression is unknown.
It was important to investigate the immunological profile of CIITA-DN pigs because SLA class II down-regulation on the CIITA-DN pig cells, especially APCs, may affect the frequencies of the lymphocyte populations, particularly by reducing the number of CD4 + T cells, as occurs in MHC class II-knockout mice. 32, 33 In such cases, they would develop impaired immunity, associated with a susceptibility to infection, resulting in it not being possible to maintain them in good health. Although CIITA-DN pigs showed a lower frequency of CD4 + T cells in the blood compared with sibling WT pigs, the difference was only 10%, and there was no difference in the frequency of CD3 + T cells. Furthermore, CIITA-DN pigs had a normal T-cell proliferative response to human stimulator cells, suggesting that CIITA-DN pigs are not immunologically compromised. In support of this conclusion, GTKO pigs transgenic for CD46 and CIITA-DN have been developed by breeding by Revivicor; these pigs are not at increased risk of infection, and breed and grow normally compared with WT pigs housed under the same conditions.
In the present study, we demonstrated that a mutated form of the hCIITA gene, coding for a protein lacking the N-terminal 335 amino acid, acts as a potent and constitutive DN suppressor of SLA class II expression in The results demonstrated that, in contrast to CIITA-DN pAECs, moderate SLA class II expression remained on PBMCs, especially on B cells. However, the residual low level of SLA class II expression (< 30-50% compared with WT) significantly reduced the stimulation associated with direct xenorecognition by hCD4 + T cells, even when compared with the alloresponse, suggesting that sensitization by passenger leucocytes might be reduced. CIITA-DN pigs may also prevent SLA class IIspecific sensitization through the indirect pathway because of down-regulation of SLA class II expression. Therefore, CIITA-DN pigs may reduce SLA class II-mediated rejection through both direct and indirect pathways. However, primate T cells may proliferate against various peptides (not only SLA class I and II) derived from pig cells through the indirect pathway.
1,2,36 Therefore, additional strategies (e.g. co-stimulatory blockade) to suppress sensitization to pig antigens expressed on host APCs through the indirect pathway will be required even when organs from CIITA-DN pigs have been transplanted.
Although the hCD4 + T-cell response to CIITA-DN pAECs was significantly reduced, characterization of hCD4 + T cells after co-culture with CIITA-DN pAECs would provide valuable information with regard to the underlying mechanism by which this effect is obtained (e.g. anergy, regulatory phenotype, or apoptosis). However, it would be preferable to carry out this investigation in an in vivo model (CIITA-DN pig to non-human primate organ Tx) rather than in vitro.
The induction of donor-specific tolerance is a recognized ultimate goal in xenoTx. 37 Down-regulation of SLA class II might affect the development of SLA class IIrelated tolerance. In the present study, the expression of SLA class II on APCs (B cells) in contrast to pAECs was preserved, although the level of SLA class II expression was lower than on APCs of WT pigs. In addition, sufficient numbers of CD4 + T cells were detected in the blood of CIITA-DN pigs to suggest that SLA class II expression on haematopoietic cells and in the thymus had been preserved. In addition, donor-specific tolerance would be associated with the expression not only of SLA class II, but also with other pig antigens. Therefore, it would be necessary to carry out further experiments to specifically investigate whether the Tx of organs from CIITA-DN pigs might interfere with the development of donor-specific tolerance in xenoTx.
CIITA has also been shown to play a role in up-regulating the expression of MHC class I. 38, 39 However, in our studies, suppression of CIITA did not have a consistent effect on SLA class I expression. Furthermore, although CIITA-independent expression of HLA-DQ has been demonstrated in Epstein-Barr virus-transformed B cells, 40 we did not see a differential effect of CIITA-DN on SLA-DR and SLA-DQ expression. Taken together, our data suggest that (i) organs/tissue/ cells from CIITA-DN pigs (under the control of a constitutive promoter and an EC-specific enhancer) will be associated with a reduced hCD4 + T-cell response, and (ii) CIITA-DN pigs are not immunocompromised. Although CIITA-DN pigs on a GTKO/CD46 background have been produced, these pigs remain suboptimal as sources of organs because thrombotic microangiopathy still occurs. XenoTx of vascularized organs from CIITA-DN pigs on a background of GTKO transgenic for a human coagulationregulatory protein (e.g. GTKO/thrombomodulin) will be necessary to confirm the beneficial effect of the CIITA-DN transgene. We suggest that (iii) organs from GTKO pigs transgenic for both human complement-regulatory and coagulation-regulatory proteins and with the CIITA-DN mutation should be significantly protected from complement-mediated lysis, the development of thrombotic microangiopathy, and the CD4 + T-cell response, and (iv) long-term pig xenograft survival with clinically acceptable levels of immunosuppression might be facilitated. 
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